Fractyl Health Stock (NASDAQ:GUTS)


RevenueFinancialsChartTranscripts

Previous Close

$1.79

52W Range

$1.74 - $14.50

50D Avg

$2.37

200D Avg

$4.29

Market Cap

$91.39M

Avg Vol (3M)

$316.71K

Beta

-

Div Yield

-

GUTS Company Profile


Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

122

IPO Date

-

Website

GUTS Performance


GUTS Financial Summary


Dec 23Dec 22Dec 21
Revenue$120.00K--
Operating Income$-50.84M$-49.38M$-36.93M
Net Income$-77.09M$-46.45M$-38.73M
EBITDA$-50.55M$-48.93M$-36.25M
Basic EPS$-17.26$-0.98$-0.81
Diluted EPS$-17.26$-0.98$-0.81

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 14, 24 | 11:01 PM
Q2 24Aug 14, 24 | 9:27 PM
Q1 24May 13, 24 | 10:37 PM